-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Benzinga·11/13/2025 13:54:48
Listen to the news
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.